Molecular Partners AG, global leader in the development of DARPins as unique next generation protein therapeutics, has enrolled the first cohorts of patients in two separate phase-I trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

The trials are investigating the safety and tolerability of a single intravitreal injection of MP0112, a DARPin which inhibits all relevant forms of vascular endothelial growth factor A (VEGF-A) with high potency. The studies will also allow a preliminary assessment of efficacy and the duration of action of MP0112.

MP0112 was engineered to have a long ocular half-life but fast systemic clearance. Thus, it has the potential to become the best-in-class inhibitor of neovascular diseases of the eye and to reduce the number of intravitreal injections needed as compared to current approved standard of care.